Basit öğe kaydını göster

dc.contributor.authorMetin, Ahmet
dc.contributor.authorDilek, Nursel
dc.contributor.authorBilgili, Serap Güneş
dc.date.accessioned2020-12-19T19:42:52Z
dc.date.available2020-12-19T19:42:52Z
dc.date.issued2018
dc.identifier.citationMetin, A., Dilek, N., & Bilgili, S. G. (2018). Recurrent candidal intertrigo: challenges and solutions. Clinical, cosmetic and investigational dermatology, 11, 175–185. https://doi.org/10.2147/CCID.S127841en_US
dc.identifier.issn1178-7015
dc.identifier.urihttps://doi.org/10.2147/CCID.S127841
dc.identifier.urihttps://hdl.handle.net/11436/1967
dc.descriptionWOS: 000430340000001en_US
dc.descriptionPubMed: 29713190en_US
dc.description.abstractIntertrigo is a common inflammatory dermatosis of opposing skin surfaces that can be caused by a variety of infectious agents, most notably candida, under the effect of mechanical and environmental factors. Symptoms such as pain and itching significantly decrease quality of life, leading to high morbidity. A multitude of predisposing factors, particularly obesity, diabetes mellitus, and immunosuppressive conditions facilitate both the occurrence and recurrence of the disease. the diagnosis of candidal intertrigo is usually based on clinical appearance. However, a range of laboratory studies from simple tests to advanced methods can be carried out to confirm the diagnosis. Such tests are especially useful in treatment-resistant or recurrent cases for establishing a differential diagnosis. the first and key step of management is identification and correction of predisposing factors. Patients should be encouraged to lose weight, followed up properly after endocrinologic treatment and intestinal colonization or peri-orificial infections should be medically managed, especially in recurrent and resistant cases. Medical treatment of candidal intertrigo usually requires topical administration of nystatin and azole group antifungals. in this context, it is also possible to use magistral remedies safely and effectively. in case of predisposing immunosuppressive conditions or generalized infections, novel systemic agents with higher potency may be required.en_US
dc.language.isoengen_US
dc.publisherDove Medical Press Ltden_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCandidaen_US
dc.subjectIntertrigoen_US
dc.subjectRecurrent candidal intertrigoen_US
dc.subjectCandidiasisen_US
dc.subjectCandidosisen_US
dc.subjectCandidal predisposalsen_US
dc.titleRecurrent candidal intertrigo: challenges and solutionsen_US
dc.typereviewen_US
dc.contributor.departmentRTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.contributor.institutionauthorDilek, Nursel
dc.identifier.doi10.2147/CCID.S127841
dc.identifier.volume11en_US
dc.identifier.startpage175en_US
dc.identifier.endpage185en_US
dc.ri.editoaen_US
dc.relation.journalClinical Cosmetic and Investigational Dermatologyen_US
dc.relation.publicationcategoryDiğeren_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster